Lisa Argnani
Overview
Explore the profile of Lisa Argnani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zoli S, Pellegrini C, Casadei B, Broccoli A, Argnani L, Nanni L, et al.
Chemotherapy
. 2023 Nov;
69(1):23-26.
PMID: 37913761
Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), there are no uniform recommendations for second-line treatment in case of relapse. Case Presentation: Here, we present the case of...
12.
Broccoli A, Argnani L, Nanni L, Stefoni V, Pellegrini C, Casadei B, et al.
Blood Adv
. 2023 Sep;
7(21):6762-6766.
PMID: 37738174
No abstract available.
13.
Lolli G, Argnani L, Gini G, Casadei B, Pellegrini C, Tani M, et al.
Hematol Oncol
. 2023 Jul;
41(5):947-950.
PMID: 37442805
No abstract available.
14.
Gentilini M, Casadei B, Morigi A, Lolli G, Ferrari M, Carella M, et al.
Chemotherapy
. 2023 Jun;
68(4):219-221.
PMID: 37311417
An endobronchial localization of Hodgkin lymphoma is rare, and few experiences since the 1900s have been reported in the literature. Here we report the first case of a relapsed/refractory Hodgkin...
15.
Argnani L, Broccoli A, Pellegrini C, Fabbri A, Puccini B, Bruna R, et al.
Hemasphere
. 2022 Nov;
6(12):e798.
PMID: 36398133
After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access...
16.
Lolli G, Ursi M, Dicataldo M, Casadei B, Storci G, Argnani L, et al.
Leuk Lymphoma
. 2022 Jul;
63(12):3012-3014.
PMID: 35866874
No abstract available.
17.
Broccoli A, Argnani L, Cross M, Janus A, Maitre E, Troussard X, et al.
Blood Adv
. 2022 May;
6(14):4224-4227.
PMID: 35584397
No abstract available.
18.
Lolli G, Casadei B, Stefoni V, Argnani L, Bonifazi F, Zinzani P
Chemotherapy
. 2022 May;
67(4):253-255.
PMID: 35537403
Hepatosplenic T-cell lymphoma is a very difficult lymphoma to deal with, almost impossible to cure. "Tandem" consolidation therapy with auto-stem cell transplant and allo-stem cell transplant can induce a long-lasting...
19.
Broccoli A, Argnani L, Coppola P, Gentilini M, Bagnato G, Lolli G, et al.
Tumori
. 2022 Apr;
109(2):249-252.
PMID: 35441544
The follow-up of the pivotal trial and large case series reports of a proportion of patients, between 5% and 9%, with relapsed or refractory Hodgkin lymphoma failing autologous stem cell...
20.
Zanetti A, Sakellariou G, Zambon A, Carrara G, Argnani L, Mantovani L, et al.
Arthritis Care Res (Hoboken)
. 2022 Apr;
75(5):1046-1051.
PMID: 35439369
Objective: Early diagnosis and tight control improve outcomes of rheumatoid arthritis (RA). However, whether establishing an early arthritis clinic (EAC) is sustainable for national health systems is not known. This...